feed,title,long_url,short_url
NPR,"FDA advisors strongly back new Alzheimerâ€™s drug, despite risks and limitations",https://www.npr.org/sections/shots-health-news/2024/06/10/g-s1-3818/fda-advisors-back-alzheimer-drug-donanemab-despite-risks,https://da.gd/8rIF3N
